Alachua

PetSmart honors service members and their families with $25,000 donation to K9s For Warriors

Retrieved on: 
Wednesday, November 9, 2022
Organization, Environment, Alachua, Assistance dog, PETS, PetSmart, Dog, Working dog, Purdue University, K9s for Warriors, PTSD, Culture, Health, Partnership, Mental health, Heidi, PetSmart Charities, Veteran, Vaccination, Solution, Military sexual trauma, Veterans Day, Dignity, Multimedia, Awareness, Suicide, Bottled water, Hospital, Commercial property, Online shopping, Health insurance, Phoenix

PHOENIX, Nov. 9, 2022 /PRNewswire/ -- PetSmart, the leading pet retailer, is proud to honor service members and their families every day and especially this Veterans Day.

Key Points: 
  • On Nov. 11, PetSmart will present $25,000 to K9s For Warriors , the nation's largest provider of trained service dogs for veterans.
  • The donation will help support K9s For Warriors' mission to end veteran suicide through the loving support of service dogs many of which are rescues at no cost to the service members.
  • "K9s For Warriors has the privilege every day to see the impact a Service Dog has on a veteran.
  • The donation to K9s For Warriors is just one of the initiatives PetSmart leads in support of service members and follows the creation of PetSmart's newest associate resource group SERVE, which honors the service of PetSmart associates who are veterans and their families.

PetSmart honors service members and their families with $25,000 donation to K9s For Warriors

Retrieved on: 
Wednesday, November 9, 2022
Organization, Environment, Alachua, Assistance dog, PETS, PetSmart, Dog, Working dog, Purdue University, Indiana University–Purdue University Indianapolis, K9s for Warriors, PTSD, Culture, View, Partnership, Mental health, Heidi, PetSmart Charities, Veteran, Solution, Military sexual trauma, Veterans Day, Dignity, Multimedia, Awareness, Suicide, Bottled water, Hospital, Commercial property, Online shopping, Toy, Phoenix

PHOENIX, Nov. 9, 2022 /PRNewswire/ -- PetSmart, the leading pet retailer, is proud to honor service members and their families every day and especially this Veterans Day.

Key Points: 
  • On Nov. 11, PetSmart will present $25,000 to K9s For Warriors , the nation's largest provider of trained service dogs for veterans.
  • The donation will help support K9s For Warriors' mission to end veteran suicide through the loving support of service dogs many of which are rescues at no cost to the service members.
  • "K9s For Warriors has the privilege every day to see the impact a Service Dog has on a veteran.
  • The donation to K9s For Warriors is just one of the initiatives PetSmart leads in support of service members and follows the creation of PetSmart's newest associate resource group SERVE, which honors the service of PetSmart associates who are veterans and their families.

TRI-BUILT™ Partners With K9s for Warriors, Provides Service Dogs to Veterans

Retrieved on: 
Thursday, September 29, 2022
Commercial Building & Real Estate, Construction & Property, Veterans, Urban Planning, Military, Building Systems, Architecture, Other Construction & Property, Defense, Residential Building & Real Estate, Diamond, Nasdaq, Working dog, Beacon of Hope, BECN, Fortune 500, Corporate social responsibility, Warrior, Organization, Service, Partnership, Meal, Environment, Mental health, Alachua, Military sexual trauma, Dog, K9s for Warriors, Assistance dog, Multimedia, Awareness, PTSD, Housing, Hospital, Phoenix, Beacon, Veteran, Veteran

Each month, Veterans arrive at K9s For Warriors to take part in a three-week, in-house training program at no cost to Veterans.

Key Points: 
  • Each month, Veterans arrive at K9s For Warriors to take part in a three-week, in-house training program at no cost to Veterans.
  • K9s For Warriors provides a trained Service Dog, housing, all meals, equipment, veterinary care, and training in a welcoming environment that provides essential peer-to-peer support.
  • We look forward to developing a multifaceted partnership together with Beacon that helps us save more Veterans and Service Dogs.
  • K9s For Warriors is a non-profit organization determined to end Veteran suicide, providing highly trained Service Dogs to military Veterans suffering from PTSD, traumatic brain injury and/or military sexual trauma.

American Water Charitable Foundation and American Water Military Services Group Partner with K9s For Warriors to Help Improve Veterans' Lives One Dog at a Time

Retrieved on: 
Thursday, September 15, 2022
Veterans, Pets, Utilities, Military, Philanthropy, Energy, Consumer, Foundation, Other Philanthropy, Defense, Diamond, People, Working dog, Scott Air Force Base, Joint Base Lewis–McChord, Hydro, Twitter, Wright-Patterson Air Force Base, NYSE, Policy, Fort A.P. Hill, Hill Air Force Base, Joint Base San Antonio, Community, Picatinny Arsenal, LinkedIn, Dog, Service, Partnership, American Water, Mental health, History, Water, Zenith Contract Services, Alachua, CEO, Military sexual trauma, Veteran, Vandenberg Space Force Base, Work, Foundation, K9s for Warriors, Assistance dog, Naval base, Multimedia, Awareness, Suicide, PTSD, Pharmaceutical industry, Hospital, Labrador Retriever, Phoenix, American, Facebook

Hydro is a one year old black Labrador Retriever, whose name was selected by American Water Military Services Group employees.

Key Points: 
  • Hydro is a one year old black Labrador Retriever, whose name was selected by American Water Military Services Group employees.
  • (Photo: Business Wire)
    The American Water Charitable Foundation is pleased to partner with K9s For Warriors to support our veterans and Service Dogs, said Carrie Williams, president, American Water Charitable Foundation.
  • We are delighted to partner with the American Water Charitable Foundation in selecting an organization that supports the veteran community and resonates with our team, said Steve Curtis, president, American Water Military Services Group and Contract Services Group.
  • American Water provides safe, clean, affordable and reliable water services to our customers to help keep their lives flowing.

K9S FOR WARRIORS AND SURFSIDE POLICE DEPARTMENT INTRODUCE 'OFFICER MIKE' IN THE WAKE OF THE SURFSIDE COLLAPSE ONE YEAR AGO

Retrieved on: 
Tuesday, June 21, 2022
Diamond, Dog, Heidi 4 Paws, Police, American Kennel Club, Walking, Memory, Anxiety, Veteran, K9s for Warriors, Vaginal trauma, Veterans Park, CEO, Working dog, Time, Suicide, Assistance dog, Trauma, Heidi, Man, Firefighter, MIKE, Purdue University, Town, PTSD, Indiana University–Purdue University Indianapolis, Mental health, Emotion, Warrior, Law enforcement, Laughter, Alachua, Military sexual trauma, Multimedia, Awareness, Service, Woman, Love, Pharmaceutical industry, Private investigator, Phoenix

SURFSIDE, Fla., June 21, 2022 /PRNewswire/ -- Officer Mike may be the newest member of the Surfside Police Department, but in his six months walking the beat, he has already made an undeniable impact on his fellow officers. 

Key Points: 
  • He is a fluffy goldendoodle and retired Service Dog who came to the Surfside Police Department courtesy of K9s For Warriors' Station Dog program.
  • He is trained to lower anxiety and stress among officers following the Champlain Tower collapse one year ago this week.
  • We are thrilled Officer Mike is doing just that for our officers in Surfside after experiencing such devastating loss almost one year ago."
  • Surfside Police officers were among the first to arrive at the site of the Champlain Tower collapse on June 24, 2021.

AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

Retrieved on: 
Monday, December 6, 2021
Paragon, Pharmacy, Patient, Neurotology, CEO, Ophthalmology, Commercial Club of Chicago, Risk, Technology, Achromatopsia, Forward-looking statement, ACHM, Applied Genetic Technologies Corporation, Retina, Optogenetics, SEC, Central nervous system, Bachelor of Science in Human Biology, Therapy, Annual report, COVID-19, Nasdaq, GLOBE, IRDS, LLC, Board of directors, Organization, Central nervous system disease, Board, Director, AAV, Form 10-K, Pharmaceutical Research and Manufacturers of America, Drug development, Young Presidents' Organization, CNS, DePaul University, Pharmaceutical industry, Management

A proven industry leader, Mr. Robinson served as a member of the Urovant Board of Directors prior to being appointed Urovants CEO in 2020.

Key Points: 
  • A proven industry leader, Mr. Robinson served as a member of the Urovant Board of Directors prior to being appointed Urovants CEO in 2020.
  • Prior to his role at Urovant, Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences.
  • Mr. Robinson serves on the Board of Directors for Urovant Sciences and is an advisor to BridgeBio Pharma.
  • Mr. Robinson previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and served as Chairman of PhRMAs State Committee.

AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer

Retrieved on: 
Tuesday, November 16, 2021
Gene, University, Drug development, Indiana University School of Medicine, ACHM, Genzyme, Central nervous system disease, Therapy, Form 10-K, IRDS, Neurotology, Technology, Senior, Growth, Applied Genetic Technologies Corporation, COVID-19, Research, Optogenetics, Forward-looking statement, Gene therapy, LLC, CNS, Risk, Annual report, Retina, Biotechnology, GLOBE, Retinitis pigmentosa, SEC, Central nervous system, Nasdaq, Patient, AAV, Medical device, Pharmaceutical industry

We are privileged to have an accomplished scientist and researcher join us in making transformational gene therapies a reality for patients.

Key Points: 
  • We are privileged to have an accomplished scientist and researcher join us in making transformational gene therapies a reality for patients.
  • Most recently, Dr. Scaria was the Senior Vice President and Chief Science Officer at IVERIC Bio, where he was responsible for preclinical research and development for retinal disease therapies.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).

AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting

Retrieved on: 
Friday, November 12, 2021
Safety, ACHM, American Academy of Ophthalmology, Central nervous system disease, Form 10-K, Achromatopsia, IRDS, Hospital, Neurotology, Technology, Eye, EZ, COVID-19, AAO, Optogenetics, Forward-looking statement, AAV2, LLC, CNS, Risk, Annual report, American Academy, Retina, Biotechnology, Annual general meeting, GLOBE, Retinitis pigmentosa, Therapy, SEC, Visual acuity, Central nervous system, Nasdaq, Patient, AAV, FDA, Drug development, MAIA, Applied Genetic Technologies Corporation, OCT, Pharmaceutical industry

In the non-randomized, open-label study, secondary outcome measures of clinical activity were observed through functional improvements in treated versus untreated control eyes.

Key Points: 
  • In the non-randomized, open-label study, secondary outcome measures of clinical activity were observed through functional improvements in treated versus untreated control eyes.
  • These data bring us one step closer to improving outcomes for patients losing their vision as a result of XLRP, a condition for which there are currently no treatment options.
  • At 12 months post treatment, primary outcome measures of safety demonstrated AGTC-501 to be well-tolerated at all doses.
  • Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release.

AGTC Appoints Hope D’Oyley-Gay as General Counsel

Retrieved on: 
Thursday, November 11, 2021
Compliance, GlaxoSmithKline, Drug development, University, ACHM, Associate, Central nervous system disease, General counsel, Reed Smith, Form 10-K, Achromatopsia, IRDS, Neurotology, Technology, Growth, Applied Genetic Technologies Corporation, COVID-19, Administration, Optogenetics, Forward-looking statement, IP, LLC, CNS, Risk, Retina, Annual report, Biotechnology, Company, GLOBE, Therapy, University of Pennsylvania Law School, SEC, Counsel, Central nervous system, Nasdaq, Patient, Economics, AAV, Pharmaceutical industry

We are excited to welcome Hope DOyley-Gay to AGTC, and to have the benefit of her tremendous legal expertise.

Key Points: 
  • We are excited to welcome Hope DOyley-Gay to AGTC, and to have the benefit of her tremendous legal expertise.
  • I am thrilled to join the team at AGTC, whose decades of experience in gene therapy have established a strong foundation for growth and success, said Hope DOyley-Gay, General Counsel of AGTC.
  • Previously, she was Vice President and Associate General Counsel at GlaxoSmithKline, where she supported worldwide business development on numerous strategic collaborations, including licenses, divestments, joint ventures and mergers and acquisitions.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).

AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference

Retrieved on: 
Wednesday, November 10, 2021
ACHM, Central nervous system disease, Achromatopsia, IRDS, Neurotology, Technology, Optogenetics, LLC, CNS, Retina, Conference, Biotechnology, Company, GLOBE, Therapy, Central nervous system, Nasdaq, Patient, AAV, Applied Genetic Technologies Corporation, Pharmaceutical industry

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021 at 10:40 a.m.

Key Points: 
  • GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021 at 10:40 a.m.
  • An audio webcast of the presentation can be accessed by visiting http://ir.agtc.com/events-and-presentations .
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).